Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07928622
PHASE2

Inhaled Hydrogen Therapy's Effect on Early Recurrences of Atrial Fibrillation Post-ablation.

Sponsor: University Hospital, Grenoble

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to testing the perioperative inhaled hydrogen (H2) administration's effects during atrial fibrillation ablations (AF) to reduce both early and late recurrences associated with this procedure. Researchers will compare H2 inhalation to the standard of care to see if we observe a reduction in AF recurrence after ablation but also a reduction in rehospitalizations or emergency visits for cardioversion, and consequently an improvement in quality of life. Participants will: * have an AF ablation associated to an hydrogen therapy or standard of care * complete quality of life questionnaires * record ECG on KardiaMobile© * Keep a diary of their symptoms * have a blood test * have 2 follow-up visits (after 3 and 12 months) and 2 phone calls (after 6 and 9 months)

Official title: Inhaled Hydrogen Therapy's Effect on Early Recurrences of Atrial Fibrillation Post-ablation. Phase II, Multicenter, Randomized, Controlled, Open-label Clinical Trial

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

124

Start Date

2027-01

Completion Date

2029-09

Last Updated

2026-11-10

Healthy Volunteers

No

Interventions

DRUG

Hydrogen Gas (H2)

Patients treated with inhaled hydrogen therapy in the perioperative period (initiation of inhaled hydrogen therapy from hospital admission until discharge, except in the operating room) (dosage : H2/N2 3.6%/96.4%, 1 L/min 24 hours a day)

Locations (2)

Chu Grenoble Alpes

Grenoble, Isère, France

Hopital Louis Pradel

Bron, Rhone, France